Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Cash & Equivalents: 2014-2025

Historic Cash & Equivalents for Theravance Biopharma (TBPH) over the last 12 years, with Sep 2025 value amounting to $174.8 million.

  • Theravance Biopharma's Cash & Equivalents rose 647.60% to $174.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $174.8 million, marking a year-over-year increase of 647.60%. This contributed to the annual value of $37.8 million for FY2024, which is 4.42% down from last year.
  • Theravance Biopharma's Cash & Equivalents amounted to $174.8 million in Q3 2025, which was down 38.01% from $281.9 million recorded in Q2 2025.
  • In the past 5 years, Theravance Biopharma's Cash & Equivalents registered a high of $418.5 million during Q3 2022, and its lowest value of $23.4 million during Q3 2024.
  • Over the past 3 years, Theravance Biopharma's median Cash & Equivalents value was $71.7 million (recorded in 2023), while the average stood at $103.0 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first slumped by 86.74% in 2023, then soared by 647.60% in 2025.
  • Theravance Biopharma's Cash & Equivalents (Quarterly) stood at $90.0 million in 2021, then skyrocketed by 231.45% to $298.2 million in 2022, then tumbled by 86.74% to $39.5 million in 2023, then declined by 4.42% to $37.8 million in 2024, then surged by 647.60% to $174.8 million in 2025.
  • Its Cash & Equivalents stands at $174.8 million for Q3 2025, versus $281.9 million for Q2 2025 and $110.6 million for Q1 2025.